<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00852917</url>
  </required_header>
  <id_info>
    <org_study_id>MDT3-003</org_study_id>
    <nct_id>NCT00852917</nct_id>
  </id_info>
  <brief_title>A Four-Arm Study Comparing the Analgesic Efficacy and Safety of Tramadol Once a Day 100, 200 and 300 mg Versus Placebo for the Treatment of Pain Due to Osteoarthritis of the Knee (With 7-Day Follow-up)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labopharm Inc.</source>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the analgesic efficacy and safety of Tramadol Once
      a Day 100, 200, 300 mg and Placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Global Rating of Pain for the Study Period (12 Weeks)</measure>
    <time_frame>12 weeks</time_frame>
    <description>3-item Likert-scale: &quot;How do you rate overall pain relief with the drug?&quot; with 3 possible answers: &quot;very effective&quot;, &quot;effective&quot;, or &quot;ineffective&quot;. The average of ratings at visits 2-5 was calculated as median, rounded up to the closest integer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Difference Between WOMAC Pain Subscale Score From Baseline to the End of the Study (Week 12)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of difference in WOMAC Pain Subscale score between baseline and week 12. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 100mm visual analog scale (VAS) ranging from no pain (0mm) to extreme pain (100mm). The WOMAC Pain Subscale results from the sum of 5 of the questions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Difference Between WOMAC Physical Function Subscale Score From Baseline to the End of the Study (Week 12)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of difference in WOMAC Physical Function Subscale score between baseline and week 12. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 100mm visual analog scale ranging from no difficulty (0mm) to extreme difficulty (100mm). The WOMAC Physical Function subscale results from the sum of 17 of the questions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in WOMAC Pain Subscale Score From Baseline to Intervening Visits (Visits 2-4)</measure>
    <time_frame>Week 0, week 3, week 6</time_frame>
    <description>Percentage of difference in WOMAC Pain Subscale score between baseline and intervening visits 2-4. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 100mm visual analog scale ranging from no pain (0mm) to extreme pain (100mm). The WOMAC Pain Subscale results from the sum of 5 questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in WOMAC Physical Function Subscale Score From Baseline to Intervening Visits (Visits 2-4)</measure>
    <time_frame>Week 0, week 3, week 6</time_frame>
    <description>Percentage of difference in WOMAC Physical Function Subscale score between baseline and intervening visits 2-4. The WOMAC scale is a 24-item questionnaire divided in 3 subscales. The WOMAC Physical Function Subscale comprises 17 questions each rated on a 100mm visual analog scale (VAS) ranging from no difficulty (0mm) to extreme difficulty (100mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Dose Effect Using 24-hour VAS Pain Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients rated their knee pain by marking a 100mm Visual Analogue Scale, ranging from no pain (0mm) to extreme pain (100mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Rating of Pain Relief</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Investigator Global Rating of Pain is a 3-item Likert-scale to answer the following question: &quot;How do you rate this patient's overall pain relief with the drug?&quot; with 3 possible answers: &quot;very effective&quot;, &quot;effective&quot;, or &quot;ineffective&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dropout Rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Reasons for withdrawal from the trial were collected</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">552</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1: Tramadol Once A Day 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Tramadol Once A Day 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3: Tramadol Once A Day 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Once A Day</intervention_name>
    <description>One Tramadol Once A Day tablet at randomized dose daily.</description>
    <arm_group_label>1: Tramadol Once A Day 100mg</arm_group_label>
    <arm_group_label>2: Tramadol Once A Day 200mg</arm_group_label>
    <arm_group_label>3: Tramadol Once A Day 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One Placebo tablet daily.</description>
    <arm_group_label>4: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or Females between the ages of 40-75 with a diagnosis of moderate to severe
             osteoarthritis of the knee, consistent with the ACR Clinical Classification Criteria
             for Arthritis of the Knee:

               -  Current knee pain.

               -  Less than 30 minutes of morning stiffness with or without crepitus on active
                  motion.

               -  Confirmation either by arthroscopy or radiologist's report (X-rays showing
                  osteophytes, joint space narrowing or subchondral bone sclerosis {eburnation})
                  within five years prior to entry into the study.

          2. CRP &lt; 8 ug/mL (if available at local lab) or ESR &lt; 40 mm/hr.

          3. Total WOMAC (Western Ontario and McMaster University Osteoarthritis Index) Pain
             Subscale Score of &gt; 150 mm at Baseline corresponding with moderate to severe
             Osteoarthritis.

          4. Oral and written language comprehension at a level sufficient to comply with the
             protocol and complete study-related materials.

          5. REB approval of the written Informed Consent Form in Spanish or English which was
             signed and dated by the patient and Investigator, prior to study participation.

        Exclusion Criteria:

          1. Known rheumatoid arthritis or any other rheumatoid disease.

          2. Secondary arthritis i.e. any of the following: septic arthritis; inflammatory joint
             disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia;
             Wilson's disease; ochronosis; haemochromatosis; osteochondromatosis; or collagen gene
             mutations.

          3. Evidence of effusion greater than 15 cc upon physical examination of the joint at
             Baseline (Visit 1).

          4. BMI greater than or equal to 38.

          5. Major illness, requiring hospitalization during the 3 months before commencement of
             the screening period.

          6. Unwillingness to stop taking pain medication (for arthritis or other types of pain) or
             was unwilling to stop taking other medications for the treatment of OA.

          7. Previous failure or discontinuation (due to adverse events) of tramadol HCl therapy.

          8. Treatment within the last 3 weeks with any of the following medications: monoamine
             oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds (e.g.
             cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake inhibitors;
             or any other drug that reduces seizure threshold.

          9. Treatment with another investigational agent within the last 30 days.

         10. A history of seizure disorder other than Infantile Febrile Seizures.

         11. Previous or current opioid dependency.

         12. Bowel disease causing malabsorption.

         13. Pregnancy or lactating or childbearing potential and unwilling to utilize a medically
             approved method of contraception during participation in this clinical trial.

         14. Significant liver disease, defined as active hepatitis or elevated liver enzymes &gt;3
             times the upper boundary of the normal range.

         15. Significant renal disease, defined as creatinine clearance &lt;30 mL/min as estimated by
             the method of Levey et al., 1999.

         16. Current substance abuse or dependence, other than nicotine.

         17. Allergy or adverse reaction to tramadol or any structurally similar drugs e.g.
             opiates.

         18. Any other condition that, in the opinion of the Investigators, would have adversely
             affected the patient's ability to complete the study or its measures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=9048</url>
    <description>Approved labelling</description>
  </link>
  <results_reference>
    <citation>Fishman RL, Kistler CJ, Ellerbusch MT, Aparicio RT, Swami SS, Shirley ME, Jain AK, Fortier L, Robertson S, Bouchard S. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (Tramadol Contramid OAD). J Opioid Manag. 2007 Sep-Oct;3(5):273-80.</citation>
    <PMID>18181382</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2009</study_first_submitted>
  <study_first_submitted_qc>February 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2009</study_first_posted>
  <results_first_submitted>April 8, 2009</results_first_submitted>
  <results_first_submitted_qc>April 8, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2009</results_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain due to Osteoarthritis of the Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1: Tramadol Once A Day 100mg</title>
        </group>
        <group group_id="P2">
          <title>2: Tramadol Once A Day 200mg</title>
        </group>
        <group group_id="P3">
          <title>3: Tramadol Once A Day 300mg</title>
        </group>
        <group group_id="P4">
          <title>4: Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="93"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1: Tramadol Once A Day 100mg</title>
        </group>
        <group group_id="B2">
          <title>2: Tramadol Once A Day 200mg</title>
        </group>
        <group group_id="B3">
          <title>3: Tramadol Once A Day 300mg</title>
        </group>
        <group group_id="B4">
          <title>4: Placebo</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="108"/>
            <count group_id="B4" value="227"/>
            <count group_id="B5" value="552"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="136"/>
                    <measurement group_id="B5" value="327.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="225.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.9" spread="8.3"/>
                    <measurement group_id="B2" value="61.1" spread="9.1"/>
                    <measurement group_id="B3" value="60.3" spread="9.4"/>
                    <measurement group_id="B4" value="61.1" spread="9.7"/>
                    <measurement group_id="B5" value="61.3" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="140"/>
                    <measurement group_id="B5" value="344.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="208.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Global Rating of Pain for the Study Period (12 Weeks)</title>
        <description>3-item Likert-scale: &quot;How do you rate overall pain relief with the drug?&quot; with 3 possible answers: &quot;very effective&quot;, &quot;effective&quot;, or &quot;ineffective&quot;. The average of ratings at visits 2-5 was calculated as median, rounded up to the closest integer.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale)</population>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol Once A Day 100mg</title>
          </group>
          <group group_id="O2">
            <title>2: Tramadol Once A Day 200mg</title>
          </group>
          <group group_id="O3">
            <title>3: Tramadol Once A Day 300mg</title>
          </group>
          <group group_id="O4">
            <title>4: Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Rating of Pain for the Study Period (12 Weeks)</title>
          <description>3-item Likert-scale: &quot;How do you rate overall pain relief with the drug?&quot; with 3 possible answers: &quot;very effective&quot;, &quot;effective&quot;, or &quot;ineffective&quot;. The average of ratings at visits 2-5 was calculated as median, rounded up to the closest integer.</description>
          <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ineffective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Difference Between WOMAC Pain Subscale Score From Baseline to the End of the Study (Week 12)</title>
        <description>Percentage of difference in WOMAC Pain Subscale score between baseline and week 12. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 100mm visual analog scale (VAS) ranging from no pain (0mm) to extreme pain (100mm). The WOMAC Pain Subscale results from the sum of 5 of the questions.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale). Missing Values at Last Visit Imputed by Individual Last Post Baseline Value.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol Once A Day 100mg</title>
          </group>
          <group group_id="O2">
            <title>2: Tramadol Once A Day 200mg</title>
          </group>
          <group group_id="O3">
            <title>3: Tramadol Once A Day 300mg</title>
          </group>
          <group group_id="O4">
            <title>4: Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage Difference Between WOMAC Pain Subscale Score From Baseline to the End of the Study (Week 12)</title>
          <description>Percentage of difference in WOMAC Pain Subscale score between baseline and week 12. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 100mm visual analog scale (VAS) ranging from no pain (0mm) to extreme pain (100mm). The WOMAC Pain Subscale results from the sum of 5 of the questions.</description>
          <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale). Missing Values at Last Visit Imputed by Individual Last Post Baseline Value.</population>
          <units>Percentage difference in WOMAC Pain</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" spread="50.2"/>
                    <measurement group_id="O2" value="42.8" spread="46.4"/>
                    <measurement group_id="O3" value="46.0" spread="39.9"/>
                    <measurement group_id="O4" value="32.3" spread="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in WOMAC Pain Subscale Score From Baseline to Intervening Visits (Visits 2-4)</title>
        <description>Percentage of difference in WOMAC Pain Subscale score between baseline and intervening visits 2-4. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 100mm visual analog scale ranging from no pain (0mm) to extreme pain (100mm). The WOMAC Pain Subscale results from the sum of 5 questions.</description>
        <time_frame>Week 0, week 3, week 6</time_frame>
        <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale)</population>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol Once A Day 100mg</title>
          </group>
          <group group_id="O2">
            <title>2: Tramadol Once A Day 200mg</title>
          </group>
          <group group_id="O3">
            <title>3: Tramadol Once A Day 300mg</title>
          </group>
          <group group_id="O4">
            <title>4: Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in WOMAC Pain Subscale Score From Baseline to Intervening Visits (Visits 2-4)</title>
          <description>Percentage of difference in WOMAC Pain Subscale score between baseline and intervening visits 2-4. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 100mm visual analog scale ranging from no pain (0mm) to extreme pain (100mm). The WOMAC Pain Subscale results from the sum of 5 questions.</description>
          <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale)</population>
          <units>Percentage difference in WOMAC Pain</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="41.1"/>
                    <measurement group_id="O2" value="34.5" spread="41.5"/>
                    <measurement group_id="O3" value="33.0" spread="44.6"/>
                    <measurement group_id="O4" value="19.4" spread="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (Visit 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" spread="39.2"/>
                    <measurement group_id="O2" value="46.4" spread="37.7"/>
                    <measurement group_id="O3" value="51.7" spread="41.9"/>
                    <measurement group_id="O4" value="37.8" spread="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Visit 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2" spread="39.3"/>
                    <measurement group_id="O2" value="48.8" spread="39.8"/>
                    <measurement group_id="O3" value="57.2" spread="37.6"/>
                    <measurement group_id="O4" value="44.7" spread="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in WOMAC Physical Function Subscale Score From Baseline to Intervening Visits (Visits 2-4)</title>
        <description>Percentage of difference in WOMAC Physical Function Subscale score between baseline and intervening visits 2-4. The WOMAC scale is a 24-item questionnaire divided in 3 subscales. The WOMAC Physical Function Subscale comprises 17 questions each rated on a 100mm visual analog scale (VAS) ranging from no difficulty (0mm) to extreme difficulty (100mm).</description>
        <time_frame>Week 0, week 3, week 6</time_frame>
        <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale)</population>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol Once A Day 100mg</title>
          </group>
          <group group_id="O2">
            <title>2: Tramadol Once A Day 200mg</title>
          </group>
          <group group_id="O3">
            <title>3: Tramadol Once A Day 300mg</title>
          </group>
          <group group_id="O4">
            <title>4: Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in WOMAC Physical Function Subscale Score From Baseline to Intervening Visits (Visits 2-4)</title>
          <description>Percentage of difference in WOMAC Physical Function Subscale score between baseline and intervening visits 2-4. The WOMAC scale is a 24-item questionnaire divided in 3 subscales. The WOMAC Physical Function Subscale comprises 17 questions each rated on a 100mm visual analog scale (VAS) ranging from no difficulty (0mm) to extreme difficulty (100mm).</description>
          <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale)</population>
          <units>Percentage difference in WOMAC Physical</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Visit 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="36.8"/>
                    <measurement group_id="O2" value="29.8" spread="35.6"/>
                    <measurement group_id="O3" value="34.5" spread="35.9"/>
                    <measurement group_id="O4" value="17.2" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (Visit 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" spread="37.9"/>
                    <measurement group_id="O2" value="43.5" spread="37.1"/>
                    <measurement group_id="O3" value="50.4" spread="36.8"/>
                    <measurement group_id="O4" value="34.4" spread="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (Visit 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" spread="37.6"/>
                    <measurement group_id="O2" value="44.2" spread="40.0"/>
                    <measurement group_id="O3" value="53.5" spread="58.9"/>
                    <measurement group_id="O4" value="39.5" spread="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Dose Effect Using 24-hour VAS Pain Questionnaire</title>
        <description>Patients rated their knee pain by marking a 100mm Visual Analogue Scale, ranging from no pain (0mm) to extreme pain (100mm).</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale). Missing Values at Last Visit Imputed by Individual Last Post Baseline Value.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol Once A Day 100mg</title>
          </group>
          <group group_id="O2">
            <title>2: Tramadol Once A Day 200mg</title>
          </group>
          <group group_id="O3">
            <title>3: Tramadol Once A Day 300mg</title>
          </group>
          <group group_id="O4">
            <title>4: Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Multiple Dose Effect Using 24-hour VAS Pain Questionnaire</title>
          <description>Patients rated their knee pain by marking a 100mm Visual Analogue Scale, ranging from no pain (0mm) to extreme pain (100mm).</description>
          <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale). Missing Values at Last Visit Imputed by Individual Last Post Baseline Value.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lunchtime (last individual visit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" spread="29.4"/>
                    <measurement group_id="O2" value="32.0" spread="25.2"/>
                    <measurement group_id="O3" value="34.4" spread="28.6"/>
                    <measurement group_id="O4" value="38.9" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bed time (last individual visit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0" spread="31.4"/>
                    <measurement group_id="O2" value="34.3" spread="26.0"/>
                    <measurement group_id="O3" value="34.7" spread="29.9"/>
                    <measurement group_id="O4" value="41.9" spread="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before next morning dose (last individual visit)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="31.3"/>
                    <measurement group_id="O2" value="34.3" spread="27.6"/>
                    <measurement group_id="O3" value="34.8" spread="29.1"/>
                    <measurement group_id="O4" value="40.6" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Global Rating of Pain Relief</title>
        <description>The Investigator Global Rating of Pain is a 3-item Likert-scale to answer the following question: &quot;How do you rate this patient’s overall pain relief with the drug?&quot; with 3 possible answers: &quot;very effective&quot;, &quot;effective&quot;, or &quot;ineffective&quot;.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale)</population>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol Once A Day 100mg</title>
          </group>
          <group group_id="O2">
            <title>2: Tramadol Once A Day 200mg</title>
          </group>
          <group group_id="O3">
            <title>3: Tramadol Once A Day 300mg</title>
          </group>
          <group group_id="O4">
            <title>4: Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Rating of Pain Relief</title>
          <description>The Investigator Global Rating of Pain is a 3-item Likert-scale to answer the following question: &quot;How do you rate this patient’s overall pain relief with the drug?&quot; with 3 possible answers: &quot;very effective&quot;, &quot;effective&quot;, or &quot;ineffective&quot;.</description>
          <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ineffective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Difference Between WOMAC Physical Function Subscale Score From Baseline to the End of the Study (Week 12)</title>
        <description>Percentage of difference in WOMAC Physical Function Subscale score between baseline and week 12. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 100mm visual analog scale ranging from no difficulty (0mm) to extreme difficulty (100mm). The WOMAC Physical Function subscale results from the sum of 17 of the questions.</description>
        <time_frame>12 weeks</time_frame>
        <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale). Missing Values at Last Visit Imputed by Individual Last Post Baseline Value.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol Once A Day 100mg</title>
          </group>
          <group group_id="O2">
            <title>2: Tramadol Once A Day 200mg</title>
          </group>
          <group group_id="O3">
            <title>3: Tramadol Once A Day 300mg</title>
          </group>
          <group group_id="O4">
            <title>4: Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage Difference Between WOMAC Physical Function Subscale Score From Baseline to the End of the Study (Week 12)</title>
          <description>Percentage of difference in WOMAC Physical Function Subscale score between baseline and week 12. The WOMAC scale is a 24-item questionnaire divided in 3 subscales, using a 100mm visual analog scale ranging from no difficulty (0mm) to extreme difficulty (100mm). The WOMAC Physical Function subscale results from the sum of 17 of the questions.</description>
          <population>The analysis was performed using the full analysis population (All randomized patients who received at least one dose of the assigned study medication and had at least one post Baseline assessment of any functional scale). Missing Values at Last Visit Imputed by Individual Last Post Baseline Value.</population>
          <units>Percentage difference in WOMAC Physical</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" spread="46.1"/>
                    <measurement group_id="O2" value="42.0" spread="39.5"/>
                    <measurement group_id="O3" value="38.7" spread="70.0"/>
                    <measurement group_id="O4" value="30.9" spread="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dropout Rate</title>
        <description>Reasons for withdrawal from the trial were collected</description>
        <time_frame>12 weeks</time_frame>
        <population>Safety population: all randomized patients who received at least one dose of the assigned study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Tramadol Once A Day 100mg</title>
          </group>
          <group group_id="O2">
            <title>2: Tramadol Once A Day 200mg</title>
          </group>
          <group group_id="O3">
            <title>3: Tramadol Once A Day 300mg</title>
          </group>
          <group group_id="O4">
            <title>4: Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Dropout Rate</title>
          <description>Reasons for withdrawal from the trial were collected</description>
          <population>Safety population: all randomized patients who received at least one dose of the assigned study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lack of efficacy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                    <measurement group_id="O2" value="9.9"/>
                    <measurement group_id="O3" value="10.2"/>
                    <measurement group_id="O4" value="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient request</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="7.2"/>
                    <measurement group_id="O3" value="9.3"/>
                    <measurement group_id="O4" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigator initiated discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="1.9"/>
                    <measurement group_id="O4" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="18.0"/>
                    <measurement group_id="O3" value="32.4"/>
                    <measurement group_id="O4" value="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1: Tramadol Once A Day 100mg</title>
        </group>
        <group group_id="E2">
          <title>2: Tramadol Once A Day 200mg</title>
        </group>
        <group group_id="E3">
          <title>3: Tramadol Once A Day 300mg</title>
        </group>
        <group group_id="E4">
          <title>4: Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="0"/>
                <counts group_id="E3" subjects_affected="1"/>
                <counts group_id="E4" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction Not Otherwise Specified (NOS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Gastritis Not Otherwise Specified (NOS)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30"/>
                <counts group_id="E2" subjects_affected="55"/>
                <counts group_id="E3" subjects_affected="56"/>
                <counts group_id="E4" subjects_affected="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="111"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E2" events="34" subjects_affected="22" subjects_at_risk="111"/>
                <counts group_id="E3" events="36" subjects_affected="28" subjects_at_risk="108"/>
                <counts group_id="E4" events="18" subjects_affected="13" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E3" events="21" subjects_affected="20" subjects_at_risk="108"/>
                <counts group_id="E4" events="13" subjects_affected="9" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="111"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" events="21" subjects_affected="18" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submitting results communications, the investigator shall allow Labopharm at least 30 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm’s ability to patent any invention related to the study, the publication or disclosure will be modified or delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm’s confidential information</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Regulatory Affairs</name_or_title>
      <organization>Labopharm Inc.</organization>
      <phone>1 450 686 1017</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

